Freeline Therapeutics Holdings (Freeline Therapeutics Holdings) Total Liabilities : $19.18 Mil (As of Sep. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Freeline Therapeutics Holdings Total Liabilities?

Freeline Therapeutics Holdings's Total Liabilities for the quarter that ended in Sep. 2023 was $19.18 Mil.

Freeline Therapeutics Holdings's quarterly Total Liabilities declined from Mar. 2023 ($25.38 Mil) to Jun. 2023 ($20.64 Mil) and declined from Jun. 2023 ($20.64 Mil) to Sep. 2023 ($19.18 Mil).

Freeline Therapeutics Holdings's annual Total Liabilities increased from Dec. 2020 ($18.81 Mil) to Dec. 2021 ($20.68 Mil) and increased from Dec. 2021 ($20.68 Mil) to Dec. 2022 ($34.23 Mil).

Freeline Therapeutics Holdings Total Liabilities Historical Data

The historical data trend for Freeline Therapeutics Holdings's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Freeline Therapeutics Holdings Total Liabilities Chart

Freeline Therapeutics Holdings Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Total Liabilities

9.16

12.43

18.81

20.68

34.23

Freeline Therapeutics Holdings Quarterly Data
	Dec18	Jun19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Total Liabilities	Get a 7-Day Free Trial													31.49	34.23	25.38	20.64	19.18

Freeline Therapeutics Holdings Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Freeline Therapeutics Holdings's Total Liabilities for the fiscal year that ended in Dec. 2022 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	30.966	+	(3.261	+	-4.4408920985006E-15
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	34.23

Total Liabilities	=	Total Assets (A: Dec. 2022 )	-	Total Equity (A: Dec. 2022 )
	=	86.641	-	52.414
	=	34.23

Freeline Therapeutics Holdings's Total Liabilities for the quarter that ended in Sep. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	17.477	+	(1.702	+	-1.7763568394003E-15
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	19.18

Total Liabilities	=	Total Assets (Q: Sep. 2023 )	-	Total Equity (Q: Sep. 2023 )
	=	49.219	-	30.04
	=	19.18

Freeline Therapeutics Holdings Total Liabilities Related Terms

Thank you for viewing the detailed overview of Freeline Therapeutics Holdings's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Freeline Therapeutics Holdings (Freeline Therapeutics Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Freeline Therapeutics Holdings PLC (NAS:FRLN) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

N/A

Address

Gunnels Wood Road, Sycamore House, Stevenage, Hertfordshire, GBR, SG1 2BP

Website

https://www.freeline.life

Freeline Therapeutics Holdings PLC is a clinical-stage biotechnology company developing transformative adeno-associated virus (AAV) vector-mediated gene therapies for patients suffering from inherited systemic debilitating diseases. Its lead product candidates are FLT180a for the treatment of hemophilia B, FLT190 for the treatment of Fabry disease and FLT201 for the treatment of Gaucher disease Type 1.